CD274 and neoplasm: Mice treated with a combination of anti-PD-1 and cabozantinib or triple treatment (chemotherapy, anti-PD-1 and cabozantinib) exhibited significantly decreased tumor weights (Figure 1A), increased EpCAM/PD-L1-expressing cell death (Figure 1B) and increased PMN-MDSC death (Figure 1C).